{"title":"ASAM convenes in D.C. to discuss opioid crisis with lawmakers","authors":"Alison Knopf","doi":"10.1002/adaw.34275","DOIUrl":"https://doi.org/10.1002/adaw.34275","url":null,"abstract":"<p>Late last month, representatives of the American Society of Addiction Medicine (ASAM) convened in Washington, D.C., to meet on three main topics: utilizing telemedicine to treat opioid use disorder (OUD) with medications, making methadone treatment more accessible for patients with OUD (meaning, remove opioid treatment programs [OTPs] as the sole prescribers), and covering residential treatment for addiction for Medicare patients.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 38","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recovery support groups step up in wake of Minn. agency shutdown","authors":"Gary Enos","doi":"10.1002/adaw.34272","DOIUrl":"https://doi.org/10.1002/adaw.34272","url":null,"abstract":"<p>Last month's sudden closure of a venture capital-fueled company that had rapidly become one of Minnesota's most prominent providers of peer recovery support services has left clients and peer specialists scrambling, and has community leaders wondering if industry reforms could prevent similar crises in the future.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 38","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Case You Haven't Heard…","authors":"","doi":"10.1002/adaw.34277","DOIUrl":"https://doi.org/10.1002/adaw.34277","url":null,"abstract":"<p>An industry trade show was the stage used to promote unauthorized e-cigarette products, and the Food and Drug Administration (FDA) has cracked down by sending warning letters to the manufacturers and retailers. “Regulated industry should be aware that CTP [Center for Tobacco Products] obtains leads that inform investigations from many sources, including trade shows,” said John Verbeten, director of CTP's Office of Compliance and Enforcement. “We remain committed to identifying and taking action against those breaking the law, including at these events.” The FDA CTP staff attended the trade show. They noted that regulated entities must comply with all applicable requirements under the Federal Food, Drug, and Cosmetic Act. Under these requirements, the sale and distribution of unauthorized tobacco products is illegal, including at industry events such as trade shows or expositions. The FDA also announced the issuance of warning letters to five online retailers for selling unauthorized e-cigarette products popular with youth. The FDA is engaging in ongoing efforts to prevent retailers and others from supplying unauthorized e-cigarettes. The FDA has issued more than 690 warning letters and more than 140 civil money penalty actions. The FDA has authorized 34 e-cigarette products and devices, and these are the only ones that can be lawfully marketed in the United States. For that list, go to https://digitalmedia.hhs.gov/tobacco/print_materials/CTP-250?locale=en.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 38","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"NIDA study: Higher doses of buprenorphine beneficial","authors":"Alison Knopf","doi":"10.1002/adaw.34273","DOIUrl":"https://doi.org/10.1002/adaw.34273","url":null,"abstract":"<p>Researchers have found that higher doses of buprenorphine for people with opioid use disorder (OUD) are associated with lower rates of future emergency department (ED) and inpatient care for behavioral health problems.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 38","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lethal fentanyl analog shows increase across U.S.","authors":"Alison Knopf","doi":"10.1002/adaw.34266","DOIUrl":"https://doi.org/10.1002/adaw.34266","url":null,"abstract":"<p>According to urine drug tests, carfentanil, a lethal illegal analog of fentanyl, is surging across the United States. A Sept. 24 Millennium Health <i>Signals Alert</i> reported an uptick in detections since the substance reemerged in 2023.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 37","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142430184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Coming Up…","authors":"","doi":"10.1002/adaw.34269","DOIUrl":"https://doi.org/10.1002/adaw.34269","url":null,"abstract":"<p>The <b>Addiction Health Services Research Conference</b> will be held <b>October 16-18</b> in San Francisco. For more information, go to https://www.ahsrconference.org/2024/</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 37","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142430259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"STAR Plus Scholarship Act announced","authors":"Alison Knopf","doi":"10.1002/adaw.34268","DOIUrl":"https://doi.org/10.1002/adaw.34268","url":null,"abstract":"<p>On Sept. 12, U.S. Representatives Andrea Salinas (D-Oregon) and Marc Molinaro (R-New York) introduced the Substance Use Disorder Treatment and Recovery (STAR) Plus Scholarship Act. This bill aims to establish a new scholarship program for students studying in the fields of mental health, behavioral health, or substance use disorder treatment. The STAR Loan Repayment Program, administered by the Health Resources and Services Administration, has consistently advocated for the creation of a scholarship program to accompany the loan repayment program. “NAADAC is excited and proud to support the STAR Plus Scholarship Act, as creation of these scholarship opportunities is an essential step towards building a more robust and well-trained addiction workforce,” said Terrence Walton, MSW, NAADAC's executive director. “NAADAC applauds Representatives Salinas and Molinaro for their leadership and recognition of the meaningful difference this policy solution will make in countless lives.”</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 37","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142430258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Methadone or buprenorphine preferred over naltrexone by inmates","authors":"Alison Knopf","doi":"10.1002/adaw.34262","DOIUrl":"https://doi.org/10.1002/adaw.34262","url":null,"abstract":"<p>When CODAC Behavioral Healthcare, the main provider of treatment services for corrections in Rhode Island, looks at its clientele with opioid use disorder (OUD), Vivitrol (depot naltrexone) is preferred by no one. The patients want either methadone or buprenorphine, CODAC CEO Linda Hurley explained in a webinar this month (for the first part of this two-part article, see <i>ADAW</i> (https://onlinelibrary.wiley.com/doi/10.1002/adaw.34254).</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 37","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142430236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The DEA should focus!","authors":"Rob Kent JD","doi":"10.1002/adaw.34265","DOIUrl":"https://doi.org/10.1002/adaw.34265","url":null,"abstract":"<p>I watched the segment this past weekend on [CBS TV's] <i>60 Minutes</i> about fentanyl and have some thoughts.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 37","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142429076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Case You Haven't Heard…","authors":"","doi":"10.1002/adaw.34270","DOIUrl":"https://doi.org/10.1002/adaw.34270","url":null,"abstract":"<p>Most people have probably heard by now that alcohol is a major risk factor for cancer, one of the top preventable risk factors, in fact. According to the 2024 edition of the <i>American Association for Cancer Research's Cancer Progress Report</i>, while cancer has gone down, preventable causes such as excessive alcohol use will results in more than two million new cases being diagnosed in the U.S. this year. The tobacco lesson has been well-learned. Now it's time for alcohol — excessive use is now the top modifiable risk factor for cancer. In 2019, 5.4% of all cancer cases diagnosed in the U.S. in 2019 were attributable to alcohol use.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 37","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142430260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：